"Shortening New Drug Development Period with AI" Boryung Pharmaceutical and Paminogen Agreement

[Asia Economy Reporter Choi Dae-yeol] Boryung Pharmaceutical announced on the 25th that it has signed a joint research agreement with the new drug development company Paminogen.

Paminogen is an artificial intelligence (AI)-based new drug development company, and the two companies plan to use a deep learning-based platform to discover new chemical structures for target proteins and optimize drugs to derive various new drug candidates. Boryung expects that research can be conducted efficiently by utilizing big data on 20 billion compound structures and approximately 160,000 drug target proteins owned by Paminogen.

This means that errors commonly made in the early stages of new drug candidate discovery can be reduced, thereby shortening development time and costs. Paminogen is a company that discovers new drug candidates based on AI and big data convergence technology and computer modeling technology, and it collaborates and conducts joint research with multiple medical institutions such as Samsung Medical Center and the Korea Institute of Radiological & Medical Sciences.

Myeong Je-hyeok, head of Boryung Pharmaceutical's New Drug Research Institute, said, "Through joint research utilizing Paminogen's AI and big data, we will increase the efficiency of new drug development and derive candidate substances in a short period of time." Kim Young-hoon, CEO of Paminogen, said, "If Boryung Pharmaceutical, which has extensive R&D experience, and Paminogen's AI deep learning-based prediction technology are combined, it will show successful results in developing global innovative new drugs."

This content was produced with the assistance of AI translation services.